THERIVA BIOLOGICS INC (TOVX) Fundamental Analysis & Valuation

NYSEARCA:TOVX • US87164U5083

Current stock price

0.3574 USD
+0 (+1.05%)
At close:
0.3473 USD
-0.01 (-2.83%)
After Hours:

This TOVX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. TOVX Profitability Analysis

1.1 Basic Checks

  • In the past year TOVX has reported negative net income.
  • TOVX had a negative operating cash flow in the past year.
  • In the past 5 years TOVX always reported negative net income.
  • In the past 5 years TOVX always reported negative operating cash flow.
TOVX Yearly Net Income VS EBIT VS OCF VS FCFTOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of TOVX (-66.03%) is worse than 63.11% of its industry peers.
  • Looking at the Return On Equity, with a value of -164.14%, TOVX is doing worse than 66.99% of the companies in the same industry.
Industry RankSector Rank
ROA -66.03%
ROE -164.14%
ROIC N/A
ROA(3y)-57.27%
ROA(5y)-46.53%
ROE(3y)-114.97%
ROE(5y)-83.41%
ROIC(3y)N/A
ROIC(5y)N/A
TOVX Yearly ROA, ROE, ROICTOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TOVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TOVX Yearly Profit, Operating, Gross MarginsTOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. TOVX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, TOVX has more shares outstanding
  • TOVX has more shares outstanding than it did 5 years ago.
  • TOVX has a worse debt/assets ratio than last year.
TOVX Yearly Shares OutstandingTOVX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TOVX Yearly Total Debt VS Total AssetsTOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -14.55, we must say that TOVX is in the distress zone and has some risk of bankruptcy.
  • TOVX has a worse Altman-Z score (-14.55) than 80.39% of its industry peers.
  • A Debt/Equity ratio of 0.11 indicates that TOVX is not too dependend on debt financing.
  • The Debt to Equity ratio of TOVX (0.11) is worse than 64.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -14.55
ROIC/WACCN/A
WACCN/A
TOVX Yearly LT Debt VS Equity VS FCFTOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.74 indicates that TOVX should not have too much problems paying its short term obligations.
  • TOVX's Current ratio of 1.74 is on the low side compared to the rest of the industry. TOVX is outperformed by 80.39% of its industry peers.
  • A Quick Ratio of 1.74 indicates that TOVX should not have too much problems paying its short term obligations.
  • TOVX has a Quick ratio of 1.74. This is in the lower half of the industry: TOVX underperforms 79.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
TOVX Yearly Current Assets VS Current LiabilitesTOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TOVX Growth Analysis

3.1 Past

  • TOVX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.11%, which is quite impressive.
EPS 1Y (TTM)79.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, TOVX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.48% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.87%
EPS Next 2Y38.88%
EPS Next 3Y24.48%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TOVX Yearly Revenue VS EstimatesTOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 2033 50M 100M 150M 200M
TOVX Yearly EPS VS EstimatesTOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -1K -2K -3K -4K

More info and screens

Find the best growth stocksShow best growing peers

1

4. TOVX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TOVX. In the last year negative earnings were reported.
  • Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOVX Price Earnings VS Forward Price EarningsTOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOVX Per share dataTOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • TOVX's earnings are expected to grow with 24.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.88%
EPS Next 3Y24.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TOVX Dividend Analysis

5.1 Amount

  • TOVX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TOVX Fundamentals: All Metrics, Ratios and Statistics

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (4/28/2026, 8:04:00 PM)

After market: 0.3473 -0.01 (-2.83%)

0.3574

+0 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-12
Inst Owners2.86%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap16.40M
Revenue(TTM)N/A
Net Income(TTM)-25.25M
Analysts82.5
Price Target2.55 (613.49%)
Short Float %5.64%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.1%
Min EPS beat(2)34.64%
Max EPS beat(2)41.57%
EPS beat(4)4
Avg EPS beat(4)44.72%
Min EPS beat(4)34.64%
Max EPS beat(4)63.73%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-64.29%
PT rev (3m)-64.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)85.07%
EPS NY rev (1m)86.8%
EPS NY rev (3m)86.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.86
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS0.34
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -66.03%
ROE -164.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.27%
ROA(5y)-46.53%
ROE(3y)-114.97%
ROE(5y)-83.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z -14.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)60.92%
Cap/Depr(5y)65.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.21%
EPS Next Y92.87%
EPS Next 2Y38.88%
EPS Next 3Y24.48%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.58%
OCF growth 3YN/A
OCF growth 5YN/A

THERIVA BIOLOGICS INC / TOVX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of THERIVA BIOLOGICS INC (TOVX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to TOVX.


Can you provide the valuation status for THERIVA BIOLOGICS INC?

ChartMill assigns a valuation rating of 1 / 10 to THERIVA BIOLOGICS INC (TOVX). This can be considered as Overvalued.


Can you provide the profitability details for THERIVA BIOLOGICS INC?

THERIVA BIOLOGICS INC (TOVX) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for TOVX stock?

The Earnings per Share (EPS) of THERIVA BIOLOGICS INC (TOVX) is expected to grow by 92.87% in the next year.